Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Feb;24(1):33-40.
doi: 10.1007/s10557-010-6221-4.

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction

Adriaan A Voors  1 , Ruud M van de Wal, Jasper W L Hartog, Richard G Vijn, Yoran M Hummel, Thijs W M Plokker, Dirk J van Veldhuisen, Wybren Jaarsma
Affiliations
Randomized Controlled Trial

Effects of eprosartan on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction

Adriaan A Voors et al. Cardiovasc Drugs Ther. 2010 Feb.

Abstract

Objective: To compare the effects of an angiotensin receptor blocker(ARB)-based regimen versus a non-ARB based regimen on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction.

Methods: 97 patients with a systolic blood pressure (SBP) > or =140 mmHg, a left ventricular ejection fraction >0.50, and echocardiographic evidence of diastolic dysfunction were randomly assignment to open-label treatment with eprosartan (with other anti-hypertensives; n = 47) or other anti-hypertensives alone (n = 50). Echocardiography, including tissue Doppler imaging (TDI), and neurohormones were done at baseline and after 6 months.

Results: Mean age was 65 (+/-10) years and 64% was female. During 6 months of treatment, SBP decreased from 157 +/- 16 to 145 +/- 18 mmHg in the eprosartan group and from 158 +/- 17 to 141 +/- 18 mmHg in the control group (both p < 0.001; p = ns between groups). Diastolic function was unaffected in both groups and there was no correlation between changes in SBP and changes in mean TDI (r = -0.06; p = 0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained largely unchanged. Change in SBP was however related to the change in NT-proBNP (r = 0.26; p = 0.019).

Conclusion: Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensive patients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Changes in systolic blood pressure (SBP) between baseline and after 6 months in the eprosartan and control group
Fig. 2
Fig. 2
Changes in diastolic function (mean tissue Doppler velocity E′ mean and E/E′) between baseline and after 6 months in the eprosartan and control group
Fig. 3
Fig. 3
Change in systolic blood pressure (SBP) from baseline to 6 months, divided in tertiles, related to changes in NT-proBNP
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Wang M, Yip G, Yu CM, Zhang Q, Zhang Y, Tse D, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol. 2005;45:272–277. doi: 10.1016/j.jacc.2004.09.059. - DOI - PubMed
    1. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46. doi: 10.1016/S0002-9343(03)00158-X. - DOI - PubMed
    1. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation. 2001;104:286–291. - PubMed
    1. Ciulla MM, Paliotti R, Esposito A, Dìez J, López B, Dahlöf B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110:552–557. doi: 10.1161/01.CIR.0000137118.47943.5C. - DOI - PubMed
    1. Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) J Hypertens. 2007;25:1958–1966. doi: 10.1097/HJH.0b013e3282170ada. - DOI - PubMed

Publication types

MeSH terms